Table 3 Adverse events (CTCAE version 3.0)
Adverse events | Grade 1–2 n (%) | Grade 3–4 n (%) |
|---|---|---|
Conjunctiva | 1 (5.3%) | 0 |
Pneumonitis/pulmonary infiltrates | 1 (5.3%) | 0 |
Neuropathy | 1 (5.3%) | 0 |
Skin cancer (basal cell carcinoma) | 0 | 1 (5.3%) |
Lymphoma | 0 | 1 (5.3%) |
Anemia | 0 | 0 |
Thrombocytopenia | 1 (5.3%) | 0 |
Leucopenia | 0 | 0 |
Hypercholesterolemia/hyperglycemia | 0 | 0 |
Headache | 11 (57.9%) | 0 |
Arterial hypertension | 1 (5.3%) | 0 |
Diarrhea | 7 (36.9%) | 0 |
Nausea/vomiting | 5 (26.4%) | 0 |
Mucositis/stomatitis | 7 (36.9%) | 2 (10.6%) |
Abnormal liver function tests | 0 | 0 |
Rash | 7 (36.9%) | 0 |
Arthralgia | 1 (5.3%) | 0 |
Flu-like syndrome | 6 (31.6%) | 0 |
Fatigue | 9 (47.4%) | 0 |
Wound healing | 2 (10.6%) | 0 |
Weight loss | 3 (15.8%) | 0 |
Insomnia | 4 (21.1%) | 0 |